UCB Partners With Cradle on AI Antibody Design
The Belgian biopharma company will apply Cradle's AI protein design platform across selected antibody discovery projects, with financial terms undisclosed.
Updated on Nov. 5, 2026 in Biotech
UCB has entered a strategic collaboration with Amsterdam-based Cradle to apply AI-driven protein design across selected antibody discovery projects. Financial terms were not disclosed, and the companies did not specify which programs, targets, or therapeutic areas will be covered.
Why it matters
High target affinity alone does not guarantee an antibody will be stable, manufacturable, or safe, and optimizing one attribute often degrades others. The partnership reflects a broader push to use computational tools to manage these tradeoffs earlier in drug development.
Cradle's Series B raised $73 million led by IVP in November 2024, bringing total funding above $100 million, while UCB reported €7.7 billion in 2025 revenue. The company's claimed 12-fold reduction in R&D timelines has not been independently verified, and the programs covered by the deal were not named.
The players
UCB
UCB is a Belgian biopharmaceutical company focused on severe immunological and central nervous system diseases, and it generated €7.7 billion in revenue in 2025.
Cradle
Cradle is an Amsterdam-based developer of an AI-driven protein design and engineering platform whose customers include Johnson & Johnson Innovative Medicine, Novo Nordisk, Grifols, and Novonesis.
The details
Under the collaboration, UCB will use Cradle's platform within selected discovery projects from hit generation through lead optimization and preclinical readiness. Experimental results from UCB scientists feed back into program-specific models in a lab-in-the-loop process.
Timeline
November 2024: Cradle closed its $73 million Series B round led by IVP.
January 2025: UCB licensed XtalFold, an AI structural modeling suite, from Ailux Biologics.
April 2026: UCB and the University of Southampton launched the Digital Antibody Research Collaboration.
November 4, 2026: The UCB and Cradle collaboration was announced.
Industry Pattern
UCB's January 2025 licensing of XtalFold from Ailux Biologics, a division of XtalPi, was an earlier step in adopting third-party AI structural tools. The Cradle deal extends that pattern from single-tool licensing to a platform applied across selected discovery projects.
For patients with severe immunological or neurological conditions, faster antibody development could eventually shorten the path to new treatments, though no timeline has been set for any specific therapy. The collaboration's programs and targets remain undisclosed, so direct effects on available medicines are not yet clear.
The takeaway
AI-driven design tools are increasingly being built into early antibody discovery, where tradeoffs between affinity, stability, and manufacturability are decided. Readers should watch for disclosed programs and independently validated timeline results before treating vendor claims as established.
Further reading
For more on how AI is reshaping drug development, explore our Biotech coverage.
Source note: This article includes information reported by BioPharm International.
